EMS providers and lawmakers warn that Gov. Lamont’s proposed Medicaid reimbursement cuts could force agencies to reduce staff ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm ...

The commercial success of the injectable peptide-based weight-loss drugs marketed by Novo Nordisk ... on the market are expensive and not always covered by insurance. Moreover, once people stop ...

Most compounded versions of popular drugs used for weight loss including Wegovy and Zepbound ... upward of $1,000 per month without insurance coverage. If insurance coverage is not an option ...

Woman says she got less expensive drug for weight loss after being denied by insurance Both Eli Lilly and Novo Nordisk now also offer consumers who lack insurance coverage the option to buy ...

GlobalData’s latest report, “Type 1 Diabetes: Seven-Market Drug Forecast and Market Analysis ... the tirzepatide group experienced an average weight loss of 21.4% and a 0.67 percentage ...

SOUTH BEND, Ind. (WNDU) - We are looking into a health alert, as the FDA has ruled compounded versions of popular drugs used for weight loss will no longer be available. We know one in eight ...

Very few people are currently being prescribed drugs for weight loss on the NHS in Scotland, research by BBC Scotland News has established. Medications like Mounjaro and Wegovy have been hailed as ...

The popular weight loss drug Ozempic ... $1.2 billion on Ozempic-like drugs for Medicaid patients next year, and some lawmakers are questioning what should be covered under a government safety ...

US FDA to Hold off Action on Weight-Loss Drug Copies Pending Court Ruling (Reuters) -The U.S. Food and Drug Administration said on Monday it will not take action against compounding pharmacies ...

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...